Thursday, January 10, 2008 1:57:07 PM
Thanks for the input Dew. I was hoping for something in the $300 - $500M range, but even at the lower end, we still have a substantial market cap improvement to look forward to. All the fundmentals look good: cash on hand, trial results to date, the growing cash flow from Hep C....
I remain impressed by the mangement team's confidence and the upbeat tone of the recent presentation.
I believe that $20 in the next 12 months is a reasonable target, if we get strong data from the comparative trial vs Sustiva.
Thanks again for all you do here.
L
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
